NCT07015528

Assessment of Drug Liking In Peri-procedural Clinical Settings

• Status: Enrolling By Invitation
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.

Detailed description

Specifically, we aim to measure differences in drug liking with a VAS (0 - 100) questionnaire. Additionally, we will monitor neural activity recording a frontal electroencephalogram (EEG) to detect changes in brain signals associated with opioid drug effects. By comparing behavioral and neurophysiological data across treatment and control groups, this study seeks to explore the therapeutic potential of this medication.

Conditions

• Drug Liking

Interventions

Type	Name	Description
DRUG	Droperidol	Medication administered as a single intravenous dose.
DRUG	Placebo	Matching Placebo given by single intravenous (IV) administration.

Timeline

• Start date: 2025-09-30
• Primary completion: 2026-07-31
• Completion: 2027-07-31
• First posted: 2025-06-11
• Last updated: 2025-12-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study